The Risk of Pervasive Trade Secret Practices Within the Life Sciences
Trade secrets offer a number of benefits for life sciences companies compared to patents, such as theoretical indefinite intellectual property protection.
biologics
-
Read more: The Risk of Pervasive Trade Secret Practices Within the Life Sciences -
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported? Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported?
Are manufacturing method patents warranted intellectual property protections, or groundless obstacles to competition?
-
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: Year in Review: Biosimilars Year in Review: Biosimilars
In November 2020, the FDA released its most recent draft guidance for industry on biosimilarity and interchangeability
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
By Ameet Sarpatwari, Charlie Lee, Frazer Tessema, and Aaron S. Kesselheim Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues relevant to current or potential future work in the Division. Below are the abstracts/summaries…
